Aviance Capital Partners LLC lifted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 3.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,208 shares of the biopharmaceutical company’s stock after purchasing an additional 2,399 shares during the period. Aviance Capital Partners LLC’s holdings in Pfizer were worth $2,864,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Fayez Sarofim & Co raised its holdings in Pfizer by 2.3% during the 1st quarter. Fayez Sarofim & Co now owns 830,730 shares of the biopharmaceutical company’s stock valued at $33,894,000 after buying an additional 18,295 shares during the period. Occidental Asset Management LLC lifted its holdings in shares of Pfizer by 9.6% in the 1st quarter. Occidental Asset Management LLC now owns 39,513 shares of the biopharmaceutical company’s stock worth $1,612,000 after buying an additional 3,452 shares during the period. Te Ahumairangi Investment Management Ltd increased its position in Pfizer by 20.7% during the 1st quarter. Te Ahumairangi Investment Management Ltd now owns 204,094 shares of the biopharmaceutical company’s stock valued at $8,327,000 after purchasing an additional 34,975 shares during the period. Wallace Advisory Group LLC boosted its position in Pfizer by 6.3% during the first quarter. Wallace Advisory Group LLC now owns 8,728 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 521 shares in the last quarter. Finally, Diligent Investors LLC boosted its stake in Pfizer by 0.5% in the first quarter. Diligent Investors LLC now owns 56,791 shares of the biopharmaceutical company’s stock valued at $2,317,000 after acquiring an additional 292 shares in the last quarter. Institutional investors own 67.80% of the company’s stock.

Get Pfizer alerts:

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on PFE shares. Jefferies Financial Group cut their target price on Pfizer from $40.00 to $38.00 in a research report on Wednesday, August 2nd. Barclays cut their price objective on shares of Pfizer from $40.00 to $38.00 in a report on Tuesday, July 11th. Morgan Stanley reduced their price objective on shares of Pfizer from $42.00 to $40.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 2nd. BMO Capital Markets dropped their price objective on shares of Pfizer from $45.00 to $44.00 and set an “outperform” rating for the company in a report on Wednesday, August 2nd. Finally, HSBC initiated coverage on Pfizer in a research report on Friday, July 14th. They issued a “buy” rating and a $50.00 target price for the company. Twelve research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $46.35.

Pfizer Trading Up 0.9 %

Shares of NYSE PFE traded up $0.33 during mid-day trading on Monday, hitting $36.99. The company’s stock had a trading volume of 10,256,501 shares, compared to its average volume of 24,306,217. The stock has a market cap of $208.84 billion, a price-to-earnings ratio of 9.75, a price-to-earnings-growth ratio of 1.22 and a beta of 0.60. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 1.82. Pfizer Inc. has a one year low of $34.65 and a one year high of $54.93. The company’s fifty day simple moving average is $36.82 and its 200-day simple moving average is $39.02.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.10. Pfizer had a net margin of 27.55% and a return on equity of 28.36%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $13.36 billion. During the same quarter last year, the firm earned $2.04 EPS. Pfizer’s quarterly revenue was down 54.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 3.33 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Friday, July 28th will be paid a $0.41 dividend. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.43%. Pfizer’s dividend payout ratio (DPR) is presently 43.62%.

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.